Palantir's DoD contracts, strong Q1 2025 growth, and competitive edge in AI-driven platforms make it a standout growth ...

Red Violet is a top pick in data analytics with strong financials, recurring revenue, and industry tailwinds. Click here to ...

Kestra Medical Technologies, Ltd. sees sales growth but struggles with losses and slowing revenue. Click for risks tied to ...

Oklo's $1B offering raises red flags including financial setbacks, regulatory hurdles, and shifting strategies amid optimism ...

Blue Owl Capital Corporation outperforms with a 2% Q1 NAV return, solid portfolio quality, low non-accruals & first-lien ...

Explore REGENXBIO's RGX-121 gene therapy for Hunter syndrome, with an FDA decision due Nov 9, 2025. Click here to read my ...

The backlog for contract oil driller Valaris remains strong. Read why recent share buybacks signal management’s confidence ...

Explore the explosive fallout between Elon Musk and Donald Trump, from political endorsements to shocking allegations, and ...

Rivian's initial promise has faded amid ongoing losses, weak BEV demand, and significant capital burn. Click here to read an ...

May jobs printed at 139,000, exceeding expectations. Job creation seems to undermine earlier prognostications that President ...

We asked Seeking Alpha analysts Kenio Fontes and Daniel Jones for their picks. Kenio Fontes: Two companies stand out for me ...

Booking Holdings' growth is slowing, with choppy bookings trends and decelerating revenue. Click here to find out why I ...